Bio-Techne Corp. (TECH) Financials
Key financial figures for Bio-Techne Corp. (Q4 2026).
Bio-Techne posted Q4 FY2026 organic revenue growth of 3% to $321.2 million alongside a definitive agreement to be acquired by Merck KGaA for $73 per share in cash (~$11.3 billion enterprise value). Q4 FY2026 net sales rose to $321.2M from $317.0M a year ago; organic revenue growth was 3% (1% as reported). Full fiscal year 2026 revenue was $1.215B, essentially flat organically versus FY2025's $1.220B. GAAP diluted EPS was $0.35 versus a $(0.11) loss in the year-ago quarter; adjusted diluted EPS was $0.52, down slightly from $0.53. Protein Sciences segment revenue grew to $231.2M (from $226.5M); Diagnostics and Spatial Biology grew to $90.1M (from $89.7M). Adjusted operating margin was 32.2%, up from 32.0% a year ago; full-year adjusted operating margin was 31.9% versus 31.6%. Figures are for Q4 FY2026, as Bio-Techne reported them.
- Revenue
- $321M
- Net Income
- $55M
- EPS
- $0.35
- Total Assets
- $2.6B
- Operating Cash Flow
- $95M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q4 FY2026 | $321M | $55M | $0.36 | 23.13% | $87M |
| Q3 FY2026 | $311M | $51M | $0.32 | 24.24% | $78M |
| Q2 FY2026 | $296M | $38M | $0.24 | 18.41% | $76M |
| Q1 FY2026 | $287M | $38M | $0.24 | 16.63% | $22M |
| Q4 FY2025 | $317M | -$18M | -$0.11 | -7.53% | $93M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2026 | $1.2B | $182M | $1.16 | 20.73% | $263M |
| FY2025 | $1.2B | $73M | $0.46 | 8.38% | $257M |
| FY2024 | $1.2B | $168M | $1.05 | 17.83% | $236M |
Frequently asked questions
What was Bio-Techne's revenue last quarter?
Bio-Techne reported revenue of $321.2 million for Q4 FY2026, up 1.3% from the same period a year earlier.
Is Bio-Techne profitable?
Yes. Bio-Techne reported net income of $54.6 million for Q4 FY2026, a net margin of 17% on revenue.
How has Bio-Techne's margin trended?
Operating margin was 23.13% in Q4 FY2026, compared with -7.53% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Bio-Techne generate?
Bio-Techne generated free cash flow of $86.9 million in Q4 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Bio-Techne Corp. on SentiSense, with up to forty quarters and twenty fiscal years of history.